Updated version of this database is available at ThpDB2

Detailed description page of THPdb

This page displays user query in tabular form.

Th1064 details
Primary information
ID1400
ThPP IDTh1064
Therapeutic Peptide/Protein NameMuromonab
SequenceHeavy Chain: QVQLQQSGAELARPGASVKMSCKASGYTFTRYTMHWV view full sequnce in fasta
Functional ClassificationIIa
Molecular Weight146189.7
Chemical FormulaC6460H9946N1720O2043S56
Isoelectric Point8.31
Hydrophobicity-0.513
Melting Point (℃)61 (FAB f
Half Life0.8 hours (mammalian reticulocytes, in vitro)
DescriptionMurine monoclonal antibody specific to CD3 T-cell lymphocyte antigens. More specifically it is a purified murine (mouse) monoclonal antibody, directed against the CD3 (T3) receptor on the surface of human T-cells (T-lymphocytes) cultured using the murine ascites method. Muromonab is 93% monomeric immune globulin G type 2a (IgG2a).
Indication/DiseaseFor treatment of organ transplant recipients, prevention of organ rejection
PharmacodynamicsUsed in organ transplant prophylaxis, Muromonab or OKT-3 binds specifically to the CD-3 complex, which is involved in antigen recognition and cell stimulation, on the surface of T lymphocytes. Immediately after administration CD-3-positive T lymphocytes are abruptly removed from circulation. It has been effective in reversing corticosteroid-resistant acute rejection in renal, liver, and cardiac transplant recipients.
Mechanism of ActionMuromonab binds to the T-cell surface glycoprotein CD3 epsilon chain. It appears to kill CD-3 positive cells by inducing Fc mediated apoptosis, antibody mediated cytotoxicity and complement-dependent cytotoxicity.
ToxicityN.A.
MetabolismMost likely removed by opsonization via the reticuloendothelial system.
AbsorptionN.A.
Volume of DistributionN.A.
ClearanceN.A.
CategoriesImmunologic Factors and Immunosuppressive Agents
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionCyclosporine with Muromonab increases the levels of cyclosporine
TargetN.A.
Information of corresponding available drug in the market
Brand NameORTHOCLONE OKT3 STERILE SOLUTION
CompanyCentocor Ortho Biotech, L.P.
Brand DiscriptionThe antibody is a biochemically purified IgG2a immunoglobulin with a heavy chain of approximately 50,000 daltons and a light chain of approximately 25,000 daltons. It is directed to a glycoprotein with a molecular weight of 20,000 in the human T cell surface which is essential for T cell functions. Because it is a monoclonal antibody preparation, ORTHOCLONE OKT3 Sterile Solution is a homogeneous, reproducible antibody product with consistent, measurable reactivity to human T cells.
Prescribed forORTHOCLONE OKT3 is indicated for the treatment of acute allograft rejection in renal transplant patients. ORTHOCLONE OKT3 is indicated for the treatment of steroid-resistant acute allograft rejection in cardiac and hepatic transplant patients.
Chemical NameN.A.
FormulationEach 5 mL ampule of ORTHOCLONE OKT3 Sterile Solution contains 5 mg (1 mg/mL) of muromonab-CD3 in a clear colorless solution which may contain a few fine translucent protein particles. Each ampule contains a buffered solution (pH 7.0 ± 0.5) of monobasic sodium phosphate (2.25 mg), dibasic sodium phosphate (9.0 mg), sodium chloride (43 mg), and polysorbate 80 (1.0 mg) in water for injection.
Physcial AppearanceORTHOCLONE OKT3 (muromonab-CD3)sterile solution is a murine monoclonal antibody to the CD3 antigen of human T cells which functions as an immunosuppressant.
Route of AdministrationFor Intravenous Use Only
Recommended DosageThe recommended dose of ORTHOCLONE OKT3 for the treatment of acute renal, steroid-resistant cardiac, or steroid-resistant hepatic allograft rejection is 5 mg per day in a single (bolus) Intravenous infusion in less than one minute for 10 to 14 days. 
Contraindicationnot given to patient which are hypersensitive to this or any other product of murine origin, have anti-mouse antibody titers ≥1:1000; are in (uncompensated) heart failure or in fluid overload, as evidenced by chest X-ray or a greater than 3 percent weight gain within the week prior to planned ORTHOCLONE OKT3 administration; have uncontrolled hypertension; have a history of seizures, or are predisposed to seizures.
Side EffectsRTHOCLONE OKT3 therapy includes adverse effects: Dyspnea(21%), nausea(19%), vomiting (19%), chest pain (14%), diarrhea (14%), tremor (13%), wheezing (13%), headache (11%), tachycardia (10%), rigor (8%), and hypertension (8%), Angina, Cardiac Arrest, Fluctuation in Blood Pressure, Heart Failure, Myocardial Infarction, Shock, Thrombosis, Coma, Encephalopathy, Epilepsy, Hypotonia, Gastrointestinal Hemorrhage, Coagulation Disorder, Lymphadenopathy, Lymphopenia, Anuria, Oliguria, Apnea, Pneumonitis, Conjunctivitis, Hearing Decreases.
Useful Linkhttp://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=17321
PubMed ID22531442, 12224444, 22531442, 21431500, 20458505, 18031137, 16862164, 16770243, 16151429
3-D StructureTh1064 (View) or (Download)
Primary information
ID1401
ThPP IDTh1064
Therapeutic Peptide/Protein NameMuromonab
SequenceHeavy Chain: QVQLQQSGAELARPGASVKMSCKASGYTFTRYTMHWV view full sequnce in fasta
Functional ClassificationIIa
Molecular Weight146189.7
Chemical FormulaC6460H9946N1720O2043S56
Isoelectric Point8.31
Hydrophobicity-0.513
Melting Point (℃)62 (FAB f
Half Life0.8 hours (mammalian reticulocytes, in vitro)
DescriptionMurine monoclonal antibody specific to CD3 T-cell lymphocyte antigens. More specifically it is a purified murine (mouse) monoclonal antibody, directed against the CD3 (T3) receptor on the surface of human T-cells (T-lymphocytes) cultured using the murine ascites method. Muromonab is 93% monomeric immune globulin G type 2a (IgG2a).
Indication/DiseaseFor treatment of organ transplant recipients, prevention of organ rejection
PharmacodynamicsUsed in organ transplant prophylaxis, Muromonab or OKT-3 binds specifically to the CD-3 complex, which is involved in antigen recognition and cell stimulation, on the surface of T lymphocytes. Immediately after administration CD-3-positive T lymphocytes are abruptly removed from circulation. It has been effective in reversing corticosteroid-resistant acute rejection in renal, liver, and cardiac transplant recipients.
Mechanism of ActionMuromonab binds to the T-cell surface glycoprotein CD3 epsilon chain. It appears to kill CD-3 positive cells by inducing Fc mediated apoptosis, antibody mediated cytotoxicity and complement-dependent cytotoxicity.
ToxicityN.A.
MetabolismMost likely removed by opsonization via the reticuloendothelial system.
AbsorptionN.A.
Volume of DistributionN.A.
ClearanceN.A.
CategoriesImmunologic Factors and Immunosuppressive Agents
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionRilonacept results in increased immunosuppressive effects; increases the risk of infection
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationN.A.
Side EffectsN.A.
Useful LinkN.A.
PubMed ID22531442, 12224444, 22531442, 21431500, 20458505, 18031137, 16862164, 16770243, 16151429
3-D StructureTh1064 (View) or (Download)
Primary information
ID1402
ThPP IDTh1064
Therapeutic Peptide/Protein NameMuromonab
SequenceHeavy Chain: QVQLQQSGAELARPGASVKMSCKASGYTFTRYTMHWV view full sequnce in fasta
Functional ClassificationIIa
Molecular Weight146189.7
Chemical FormulaC6460H9946N1720O2043S56
Isoelectric Point8.31
Hydrophobicity-0.513
Melting Point (℃)63 (FAB f
Half Life0.8 hours (mammalian reticulocytes, in vitro)
DescriptionMurine monoclonal antibody specific to CD3 T-cell lymphocyte antigens. More specifically it is a purified murine (mouse) monoclonal antibody, directed against the CD3 (T3) receptor on the surface of human T-cells (T-lymphocytes) cultured using the murine ascites method. Muromonab is 93% monomeric immune globulin G type 2a (IgG2a).
Indication/DiseaseFor treatment of organ transplant recipients, prevention of organ rejection
PharmacodynamicsUsed in organ transplant prophylaxis, Muromonab or OKT-3 binds specifically to the CD-3 complex, which is involved in antigen recognition and cell stimulation, on the surface of T lymphocytes. Immediately after administration CD-3-positive T lymphocytes are abruptly removed from circulation. It has been effective in reversing corticosteroid-resistant acute rejection in renal, liver, and cardiac transplant recipients.
Mechanism of ActionMuromonab binds to the T-cell surface glycoprotein CD3 epsilon chain. It appears to kill CD-3 positive cells by inducing Fc mediated apoptosis, antibody mediated cytotoxicity and complement-dependent cytotoxicity.
ToxicityN.A.
MetabolismMost likely removed by opsonization via the reticuloendothelial system.
AbsorptionN.A.
Volume of DistributionN.A.
ClearanceN.A.
CategoriesImmunologic Factors and Immunosuppressive Agents
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionTrastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationN.A.
Side EffectsN.A.
Useful LinkN.A.
PubMed ID22531442, 12224444, 22531442, 21431500, 20458505, 18031137, 16862164, 16770243, 16151429
3-D StructureTh1064 (View) or (Download)